GLPG (Galapagos NV) Total Receivables : $91.5 Mil (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Galapagos NV Total Receivables?

Galapagos NV's Total Receivables for the quarter that ended in Dec. 2024 was $91.5 Mil.

Galapagos NV Total Receivables Historical Data

The historical data trend for Galapagos NV's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galapagos NV Total Receivables Chart

Galapagos NV Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Receivables

Get a 7-Day Free Trial

210.95

145.31

81.93

71.60

91.47

Galapagos NV Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Receivables	Get a 7-Day Free Trial															71.60	100.05	109.30	96.81	91.47

Galapagos NV Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Galapagos NV Total Receivables Related Terms

Thank you for viewing the detailed overview of Galapagos NV's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Galapagos NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (NAS:GLPG) » Definitions » Total Receivables

Comparable Companies

Traded in Other Exchanges

GLPGF:USA GLPG:Netherlands GLPGa:UK 0JXZ:UK GXE:Germany G1LP34:Brazil GLPG:Austria

Address

Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800

Website

https://www.glpg.com

Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing medicines. The company is committed to improving patients' lives world-wide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. It derives maximum revenue from United States of America.